Related references
Note: Only part of the references are listed.The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
NEURO-ONCOLOGY (2021)
cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas
Daniel J. Brat et al.
ACTA NEUROPATHOLOGICA (2020)
Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre
Zane Jaunmuktane et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2019)
An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825
Haley Gittleman et al.
NEURO-ONCOLOGY (2017)
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
Michael Weller et al.
LANCET ONCOLOGY (2017)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Isocitrate Dehydrogenase (IDH) 1/2 Mutations as Prognostic Markers in Patients With Glioblastomas
Jun-Rui Chen et al.
MEDICINE (2016)
Glioblastoma vaccine therapy disappointment in Phase III trial
Hemi Malkki
Nature Reviews Neurology (2016)
Association of the Extent of Resection With Survival in Glioblastoma A Systematic Review and Meta-analysis
Timothy J. Brown et al.
JAMA ONCOLOGY (2016)
Glioblastoma in England: 2007-2011
Andrew Brodbelt et al.
EUROPEAN JOURNAL OF CANCER (2015)
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma A Randomized Clinical Trial
Roger Stupp et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis
Saleh A. Almenawer et al.
NEURO-ONCOLOGY (2015)
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2015)
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors
Jeanette E. Eckel-Passow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies
Liang Xia et al.
ONCOTARGET (2015)
High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
R. Stupp et al.
ANNALS OF ONCOLOGY (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Clinical Neuropathology Practice Guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers
Anna S. Berghoff et al.
CLINICAL NEUROPATHOLOGY (2013)
The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis
Kui Zhang et al.
FAMILIAL CANCER (2013)
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis
Hong-Bin Cheng et al.
TUMOR BIOLOGY (2013)
Glioblastoma: Clinical characteristics, prognostic factors and survival in 492 patients
Andreas M. Stark et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2012)
Glioblastoma survival in the United States before and during the temozolomide era
Derek R. Johnson et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
Annika Malmstrom et al.
LANCET ONCOLOGY (2012)
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
Wolfgang Wick et al.
LANCET ONCOLOGY (2012)
VALIDATION AND SIMPLIFICATION OF THE RADIATION THERAPY ONCOLOGY GROUP RECURSIVE PARTITIONING ANALYSIS CLASSIFICATION FOR GLIOBLASTOMA
Jing Li et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Multiple imputation using chained equations: Issues and guidance for practice
Ian R. White et al.
STATISTICS IN MEDICINE (2011)
IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
Sumihito Nobusawa et al.
CLINICAL CANCER RESEARCH (2009)
Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network
Michael Weller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma
Graziella Filippini et al.
NEURO-ONCOLOGY (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
The 2007 WHO classification of tumours of the central nervous system
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis
KR Lamborn et al.
NEURO-ONCOLOGY (2004)
Share Paper
